Document Detail

Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group.
MedLine Citation:
PMID:  10819856     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Patients admitted with an acute episode of preterm labor who respond to early intravenously administered tocolysis remain at risk of having subsequent episodes of preterm labor and preterm delivery. Several pharmacologic agents have been used in an attempt to reduce subsequent episodes of preterm labor, and all are associated with significant side effects. Atosiban, an oxytocin receptor antagonist, is effective in the treatment of an acute episode of preterm labor. This study was designed to compare the efficacy and safety of atosiban with those of placebo maintenance therapy in women with preterm labor who achieved uterine quiescence with intravenous atosiban.
STUDY DESIGN: A multicenter, double-blind, placebo-controlled trial was designed for patients in preterm labor who responded to early intravenous treatment with atosiban. Five hundred thirteen patients were randomly assigned to receive maintenance therapy, 252 to receive atosiban, and 251 to receive matching placebo. Maintenance therapy was administered as a continuous subcutaneous infusion, via pump, of 30 microg/min to the end of 36 weeks' gestation. The primary end point was the number of days from the start of maintenance therapy until the first recurrence of labor. A secondary end point was the percentage of patients receiving subsequent intravenous atosiban therapy.
RESULTS: The time (median) from the start of maintenance treatment to the first recurrence of labor was 32.6 days with atosiban and 27.6 days with placebo (P =.02). At least one subsequent intravenous atosiban treatment was needed by 61 atosiban patients (23%) and 77 placebo patients (31%). Except for injection site reactions, adverse event profiles of atosiban and placebo were comparable. There were 4 neonatal deaths reported in the atosiban group and 5 in the placebo group after the start of maintenance therapy. Infant outcomes (including birth weight) were comparable between maintenance and treatment groups.
CONCLUSIONS: Maintenance therapy with the oxytocin receptor antagonist atosiban can prolong uterine quiescence after successful treatment of an acute episode of preterm labor with atosiban. Treatment was well tolerated.
G J Valenzuela; L Sanchez-Ramos; R Romero; H M Silver; W D Koltun; L Millar; J Hobbins; W Rayburn; G Shangold; J Wang; J Smith; G W Creasy
Related Documents :
21054956 - [application of ultrasonic monitoring in induced abortion during the first trimester].
17869256 - Urogenital and recto-vaginal fistulas in southern malawi: a report on 407 patients.
12699806 - Randomised clinical trial to assess anal sphincter function following forceps or vacuum...
12350056 - Empiric treatment of minimally abnormal papanicolaou smears with 0.75% metronidazole va...
6328686 - Recurrence of duodenal ulceration in patients on maintenance ranitidine.
20216236 - Recombinant human erythropoietin in the prevention of late anemia in intrauterine trans...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  182     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-06-15     Completed Date:  2000-06-15     Revised Date:  2014-07-28    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1184-90     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Double-Blind Method
Gestational Age
Hormone Antagonists / adverse effects,  therapeutic use*
Obstetric Labor, Premature / drug therapy*
Oxytocin / antagonists & inhibitors*
Time Factors
Tocolytic Agents / adverse effects,  therapeutic use
Treatment Outcome
Vasotocin / adverse effects,  analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Hormone Antagonists; 0/Placebos; 0/Tocolytic Agents; 50-56-6/Oxytocin; 90779-69-4/atosiban; W6S6URY8OF/Vasotocin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-b...
Next Document:  Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm lab...